MeiraGTx Holdings and Hologen to form a joint venture for $430m.

MeiraGTx Holdings, a vertically integrated, clinical-stage gene therapy company, and Hologen, a developer of generative AI capabilities for clinical medicine and pharmaceutical drug development, to form a joint venture for $430m. “We are delighted to be entering into this transformative collaboration with Hologen. Our initial focus is to increase the robustness, efficiency and probability of success of the AAV-GAD Phase 3 clinical study. The use of Hologen’s AI to elucidate brain circuitry in this complex heterogeneous disease has already significantly de-risked the AAV-GAD Phase 3 program when applied to MeiraGTx’s Phase 2 clinical data sets and has identified disease modifying changes in the physiology of the brain in response to AAV-GAD treatment,” Alexandria Forbes, MeiraGTx Holdings Co-Founder, President and CEO.